Generated with Avocode.Line 2Line 3
CNS-Logo (1)

2022 CNS Annual Meeting

October 10-12 in San Francisco
Stop by and see us at Booth #509

Rapid for Trials

Quickly Identify + Enroll Clinical Trial Candidates

Rapid for Trials* streamlines clinical trial screening and enrollment workflow.  A feature within the Rapid mobile app, Rapid for Trials delivers results from Rapid clinical modules to study team members’ mobile devices, streamlining communications, maximizing screening potential and reducing time to enrollment.

Greater Volume. Streamlined Enrollment.
Transparent Analytics

Rapid for Trials provides:

  • Custom Mobile Notifications: Alerts are sent immediately to the research team when potential study candidates are identified – with customizable alert configurations.  
  • Rapid Workflow and HIPAA-Compliant Communication: Study team members are provided access to source imaging data as well as clinical data including age, gender, NIHSS, time of stroke onset, ECG results, and consent status.
  • Real-Time Site-Level Analytics: Analytics deliver transparency of potential patient volumes at participating sites. 
  • RapidAI Team Expertise and Assistance: Our team is highly engaged in site optimization, technical and clinical support.

Clinical Trials Alert

Patient View

Clinical Trial Patient List


Drive relevant patient volume

Rapid for Trials helps identify relevant patients–enhancing the volume and quality of trial registrants.

Sharpen your funnel

Rapid offers a suite of modules to identify patients that meet study inclusion and exclusion criteria.

Streamline enrollment

 Automated quantification of eligibility criteria is available immediately to improve coordinator speed and efficiency while screening patients for enrollment.

Get site-level visibility into scan volume based on site specific inclusion and exclusion criteria.

“…Rapid has been highly accurate… it’s an essential tool.”

Blaise Baxter, MD
Diagnostic Radiologist / Neurointerventional Radiologist

“...The Rapid software may be one of the greatest breakthroughs in our field.”

Michael Frankel, MD
Professor, Department of Neurology, Emory University School of Medicine; Chief of Neurology, Grady Memorial Hospital; and Director, Marcus Stroke and Neuroscience Center

Find out more about how Rapid for Trials can help you today

Talk to an Expert
*Currently supporting the CHARM clinical trial. The CHARM trial is a Phase llll clinical study investigating BIIB093 (intravenous (IV) glibenclamide) for the prevention and treatment of severe cerebral edema in large hemispheric infarction (LHI)